The Efficacy And Safety In Early Application For Ruxolitinib In The Prevention Of GVHD And Recurrence

Objective: To study the efficacy and safety of early active application of Ruxolitinib in the prevention of GVHD and recurrence of hematological malignangcies after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods: The clinical date of 10 patients with hematological malignangcies who applied with Ruxolitinib early after allo-HSCT in the transplantation center of our hospital from 1 April 2020 to 1 April 2021 were collected.we analyse the incidence of a GVHD and c GVHD after transplantation,recurrence of primary disease,non-recurrence mortality,cytopenia,cytomegalovirus activation,Epstein-Barr virus activation,and bacterial and fungal infection in patients after transplantation.Results: Of the 10 patients,8 had high-risk acute lymphoblastic leukemia,1 had acute myeloid leukemia,and 1 had hemophagocytic syndrome.After a median follow-up of 420(240-530)days,disease relapse occurred in 2 cases,2 patients developed grade I-II a GVHD,no patient developed grade III-IV a GVHD,1 patient developed c GVHD,no patient developed EBV activation or EBV-related lymphoproliferative disease,and 3 patients developed CMV activation,no patient developed CMV viremia.Conclusion: Early active application of Ruxolitinib can safely and effectively prevent the occurrence of GVHD after allogeneic hematopoietic stem cell transplantation for hematologic malignancies,but it has limited effect on preventing recurrence of high-risk hematologic malignancies and may require synergistic effects in combination with other drugs.